Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bayer/Versant Launch New Stem Cell Company With Massive Cash Injection

Executive Summary

German giant Bayer has teamed up with investment firm Versant Ventures to launch a new stem cell company with $225m in start-up funding.


Related Content

J.P. Morgan Roundtable: Financing Challenges, And Opportunities, For Complex Therapies
Giant LEAPS For Mankind: Bayer's Malik On Breaking The Mold In R&D
Biopharma Investing In Better Success Rates Via AI, Data And New Modalities
Bayer's Weinand On Pricing, Payers And Pipelines
Start-Up Quarterly Statistics, Q4 2016
Early Stage Biopharma Financings Kept Up Multibillion-Dollar Pace In 2016
VC Roundup: Flagship’s New Fund Designed To Raise Its Stake In Startups
Head of Bayer LifeScience Center: Expect More JVs


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts